ClinicalTrials.gg
CompletedNCT03740659iPERMEUpdated Jul 7, 2020Results posted

Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery

A Phase 2 interventional study of Levofloxacin + Dexamethasone and Levofloxacin in Cataract, sponsored by NTC srl. Completed at 2 sites in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-07-07.

Sponsored by NTC srl · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.

Enrollment
10th of 34
125 · median 50
Started
2018
with 2 others
Phase 2
2 of 34
none open now
Registered
7th of 34
by date
Lead sponsor
2 of 34
NTC srl

Among the 34 studies testing dexamethasone in Cataract, this one is the 10th largest by enrollment, is one of 3 that started in 2018, is one of 2 in phase 2, and was the 7th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing dexamethasone in Cataract, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the penetration of levofloxacin and dexamethasone 21-phosphate into the aqueous humour after ocular administration in combination or as single active ingredients.

Read the detailed description

In most cases, postoperative care after cataract surgery consists of antiinflammatory and antibacterial drug therapy. The use of an ophthalmic solution containing the combination of a steroid and an antibiotic is routinely used in clinical practice; however, treatment duration could favour the emergence of antibiotic resistance. The study treatment associating a broad-spectrum antibiotic with a highly effective corticosteroid that can be used for a short period of time (one week) is therefore of considerable interest.

The aim of this study is to measure the concentrations of levofloxacin and dexamethasone in the aqueous humour after topical application of the combined ophthalmic solution and its single components.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written
  2. Male or female patients, aged ≥40 years
  3. Patient undergoing phacoemulsification
  4. Corneal thickness between 450 μm and 600 μm as measured by means of pachymetry
  5. Corneal integrity confirmed by means of fluorescein test
  6. Adequate pupil dilation assessed at screening
  7. Female patients of must have a negative pregnancy test
  8. Ability to fully understand all study procedures

Exclusion criteria

Exclusion Criteria:

  1. Corneal epithelium integrity not confirmed by fluorescein test
  2. History of corneal disease or dystrophy
  3. History of ocular trauma with corneal damage
  4. History of acute ocular inflammation (including uveitis) in the 6 months prior to screening
  5. Previous ocular surgery (including laser treatment)
  6. Glaucoma
  7. Treatment with an ophthalmic drug in the 3 months prior to screening
  8. Treatment with any topical ocular drug within 12 hours before start of cataract surgery other than study drugs and instillation of topical anaesthetic within 10 minutes before start of surgery
  9. Treatment with any topical or antibiotic drug in the 7 days prior to cataract surgery
  10. Treatment with any systemic steroid or antibiotic drug in the 7 days prior to cataract surgery
  11. Known to levofloxacin, other fluoroquinolones or dexamethasone
  12. Pregnant or lactating women
  13. Patients who have received any investigational drug during the preceding 30 days or 5 times the plasma half-life, or who have previously participated in this trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Levofloxacin + Dexamethasone

    Levofloxacin 5 mg/ml + Dexamethasone 1 mg/ml (30 μl administered twice before Limbal paracentesis). Limbal paracentesis will be performed prior to cataract surgery.

    Drug: Levofloxacin + Dexamethasone

  • Active comparator
    Levofloxacin

    Levofloxacin 5 mg/ml (30 μl administered twice before Limbal paracentesis). Limbal paracentesis will be performed prior to cataract surgery.

    Drug: Levofloxacin

  • Active comparator
    Dexamethasone

    Dexamethasone 1.14 mg/ml (26 μl administered twice before Limbal paracentesis). Limbal paracentesis will be performed prior to cataract surgery.

    Drug: Dexamethasone

Interventions

  • DrugLevofloxacin + Dexamethasone

    Drug pages: Levofloxacin · Dexamethasone

    Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.

  • Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).

    Also known as: Oftaquix®

  • Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.

    Also known as: Tamesad®

06

What researchers measure

Primary outcomes

  1. Aqueous Humour Concentration of Levofloxacin

    Defined as the concentration of levofloxacin into the aqueous humour in all the three arms: Levofloxacin + Dexamethasone, Dexamethasone and Levofloxacin.The concentration of levofloxacin has been measured by LC tandem mass spectrometry.

    Time frame: 90±15 min after the first administration of the study treatments

  2. Aqueous Humour Concentration of Dexamethasone 21-phosphate

    Defined as the concentration of dexamethasone 21-phosphate into the aqueous humour in all the three arms: Levofloxacin + Dexamethasone, Dexamethasone and Levofloxacin. The concentration of dexamethasone 21-phosphate has been measured by LC tandem mass spectrometry.

    Time frame: 90±15 min after the first administration of the study treatments

  3. Aqueous Humour Concentration of Dexamethasone

    Defined as the concentration of dexamethasone into the aqueous humour in all the three arms: Levofloxacin + Dexamethasone, Dexamethasone and Levofloxacin.The concentration of dexamethasone has been measured by LC tandem mass spectrometry.

    Time frame: 90±15 min after the first administration of the study treatments

07

Results

Posted Jul 7, 2020

Participant flow

Study Period: * Date of first enrolment: 4 September 2018 * Date study finalized (last patient last visit): 6 December 2018 Study centres: * U.O. Oculistica Universitaria, Azienda Ospedaliera Universitaria Pisana, Presidio Ospedaliero di Cisanello, Pisa; * Clinica Oculistica, Presidio Ospedale San Paolo, Milan.

Participant flow — Overall Study
MilestoneLevofloxacin + DexamethasoneLevofloxacinDexamethasone
Started424241
Completed424241
Not completed000

Outcome measures

PrimaryAqueous Humour Concentration of Levofloxacin

Defined as the concentration of levofloxacin into the aqueous humour in all the three arms: Levofloxacin + Dexamethasone, Dexamethasone and Levofloxacin.The concentration of levofloxacin has been measured by LC tandem mass spectrometry.

Time frame:
90±15 min after the first administration of the study treatments
Reported as:
Mean · nmol/mL
Aqueous Humour Concentration of Levofloxacin
nmol/mLLevofloxacin + DexamethasoneLevofloxacinDexamethasone
Aqueous Humour Concentration of Levofloxacin1.970 (1.648 to 2.292)2.151 (1.708 to 2.594)0 (0 to 0)
PrimaryAqueous Humour Concentration of Dexamethasone 21-phosphate

Defined as the concentration of dexamethasone 21-phosphate into the aqueous humour in all the three arms: Levofloxacin + Dexamethasone, Dexamethasone and Levofloxacin. The concentration of dexamethasone 21-phosphate has been measured by LC tandem mass spectrometry.

Time frame:
90±15 min after the first administration of the study treatments
Reported as:
Mean · nmol/mL
Aqueous Humour Concentration of Dexamethasone 21-phosphate
nmol/mLLevofloxacin + DexamethasoneLevofloxacinDexamethasone
Aqueous Humour Concentration of Dexamethasone 21-phosphate0 (0 to 0)0 (0 to 0)0 (0 to 0)
PrimaryAqueous Humour Concentration of Dexamethasone

Defined as the concentration of dexamethasone into the aqueous humour in all the three arms: Levofloxacin + Dexamethasone, Dexamethasone and Levofloxacin.The concentration of dexamethasone has been measured by LC tandem mass spectrometry.

Time frame:
90±15 min after the first administration of the study treatments
Reported as:
Mean · nmol/mL
Aqueous Humour Concentration of Dexamethasone
nmol/mLLevofloxacin + DexamethasoneLevofloxacinDexamethasone
Aqueous Humour Concentration of Dexamethasone0.030 (0.025 to 0.035)0 (0 to 0)0.042 (0.035 to 0.048)

Adverse events

Collected over From baseline to the study completion, approximately 2 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levofloxacin + Dexamethasone0/42 (0%)0/42 (0%)0/42 (0%)
Levofloxacin0/42 (0%)0/42 (0%)0/42 (0%)
Dexamethasone0/41 (0%)0/41 (0%)1/41 (2.4%)
Most frequent other events
Most frequent other events
EventLevofloxacin + DexamethasoneLevofloxacinDexamethasone
Mild MydriasisEye disorders0/420/421/41

Baseline characteristics

Main eligibility criteria included patients of both genders, aged ≥40 years and scheduled for phacoemulsification.

Age, Categorical
Age, Categorical(Participants)Levofloxacin + DexamethasoneLevofloxacinDexamethasoneTotal
<=18 years0000
Between 18 and 65 years74617
>=65 years353835108
Age, Continuous
Age, Continuous(years)Levofloxacin + DexamethasoneLevofloxacinDexamethasoneTotal
Mean72.45 ± 7.6075.38 ± 8.3874.59 ± 8.0074.14 ± 8.03
Sex: Female, Male
Sex: Female, Male(Participants)Levofloxacin + DexamethasoneLevofloxacinDexamethasoneTotal
Female27212169
Male15212056
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Levofloxacin + DexamethasoneLevofloxacinDexamethasoneTotal
American Indian or Alaska Native0000
Asian0112
Native Hawaiian or Other Pacific Islander0000
Black or African American0101
White424040122
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Levofloxacin + DexamethasoneLevofloxacinDexamethasoneTotal
Italy424241125
08

Study locations

2 sites
  • ASST Santi Paolo e Carlo di Milano - P.O. San Paolo di Milano
    Milano, MI 20142, Italy
  • A.O.U. Pisana - P.O. di Cisanello
    Pisa, PI 56124, Italy
09

References and documents

Publications

  • Figus M, Posarelli C, Romano D, Nardi M, Rossetti L. Aqueous humour concentrations after topical apPlication of combinEd levofloxacin-dexamethasone eye dRops and of its single components: a randoMised, assEssor-blinded, parallel-group study in patients undergoing cataract surgery: the iPERME study. Eur J Clin Pharmacol. 2020 Jul;76(7):929-937. doi: 10.1007/s00228-020-02863-7. Epub 2020 Apr 13. PubMed 32285142 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Dec 2018, 3 months.

Results were first posted in Jul 2020, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2018
First posted
Nov 14, 2018
StartActual
Sep 4, 2018
Primary completionActual
Dec 6, 2018
CompletionActual
Dec 6, 2018
Results first posted
Jul 7, 2020
Last update
Jul 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03740659
Lead sponsor
NTC srl
Responsible party
Sponsor
First posted
Nov 14, 2018
Start date
Sep 4, 2018
Primary completion
Dec 6, 2018
Completion
Dec 6, 2018
Results posted
Jul 7, 2020
Last update
Jul 7, 2020

Study contacts

Marco Nardi, Prof.
principal investigator · A.O.U. Pisana - P.O. di Cisanello

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levofloxacin · Dexamethasone

Start the discussion